Sean M. McKenna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sean M. McKenna has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Sebastian J. Pomplun
Leiden University
8 shared publications - Edith van der Nol
LACDR, Leiden University, Leiden, 2333 CC, The Netherlands
5 shared publications - Gerard J. P. van Westen
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
4 shared publications - J. Miguel Mata
Leiden University
4 shared publications - Laura H. Heitman
Leiden University
4 shared publications - Cas van der Horst
Leiden Academic Centre for Drug Research
3 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
AutoSPS-D2B: Automated Solid-Phase Synthesis Expands the Reaction Scope for Direct-to-Biology Libraries
Direct-to-biology (D2B) has emerged as a powerful accelerant in early drug discovery, bypassing compound purification to compress the design-make-test-analyse (DMTA) cycle. However, the chemistry underpinning D2B libraries is limited to just a few sequential transformations using assay-compatible reagents and solvents. By contrast, solid-phase synthesis (SPS) empowers a far broader range of reactions and is highly amenable to multistep synthesis, yet its potential as a source for D2B libraries remains largely underexplored. In this study, we develop AutoSPS-D2B, a fully automated solid-phase synthesis workflow that converts multistep, resin-bound chemistry into crude screening libraries that can be assayed directly, expanding reaction scope well beyond the reach of solution-phase D2B. We applied AutoSPS-D2B to explore several distinct chemotypes as allosteric ligands for the immuno-oncology target CCR2. Good agreement was observed in the relative binding affinity trends between crude and pure screening compounds, enabling streamlined ranking of analogues and prioritisation of hits for further investigation. When applied to the advancement of a previously underexplored CCR2 hit, AutoSPS-D2B enabled an analogue space of more than 1,700 building block combinations to be rapidly sampled, leading to optimised compounds with up to six-fold binding affinity improvements in just two DMTA cycles. This work establishes automated SPS as a versatile and efficient engine for D2B-driven hit-to-lead discovery.
- 15 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAutoSPS-D2B: Automated Solid-Phase Synthesis Expands the Reaction Scope for Direct-to-Biology Libraries
Direct-to-biology (D2B) has emerged as a powerful accelerant in early drug discovery, bypassing compound purification to compress the design-make-test-analyse (DMTA) cycle. However, the chemistry underpinning D2B libraries is limited to just a few sequential transformations using assay-compatible reagents and solvents. By contrast, solid-phase synthesis (SPS) empowers a far broader range of reactions and is highly amenable to multistep synthesis, yet its potential as a source for D2B libraries remains largely underexplored. In this study, we develop AutoSPS-D2B, a fully automated solid-phase synthesis workflow that converts multistep, resin-bound chemistry into crude screening libraries that can be assayed directly, expanding reaction scope well beyond the reach of solution-phase D2B. We applied AutoSPS-D2B to explore several distinct chemotypes as allosteric ligands for the immuno-oncology target CCR2. Good agreement was observed in the relative binding affinity trends between crude and pure screening compounds, enabling streamlined ranking of analogues and prioritisation of hits for further investigation. When applied to the advancement of a previously underexplored CCR2 hit, AutoSPS-D2B enabled an analogue space of more than 1,700 building block combinations to be rapidly sampled, leading to optimised compounds with up to six-fold binding affinity improvements in just two DMTA cycles. This work establishes automated SPS as a versatile and efficient engine for D2B-driven hit-to-lead discovery.
- Open Access
- 13 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
AutoSPS-D2B: Automated Solid-Phase Synthesis Expands the Reaction Scope for Direct-to-Biology Libraries
Direct-to-biology (D2B) has emerged as a powerful accelerant in early drug discovery, bypassing compound purification to compress the design-make-test-analyse (DMTA) cycle. However, the chemistry underpinning D2B libraries is limited to just a few sequential transformations using assay-compatible reagents and solvents. By contrast, solid-phase synthesis (SPS) empowers a far broader range of reactions and is highly amenable to multistep synthesis, yet its potential as a source for D2B libraries remains largely underexplored. In this study, we develop AutoSPS-D2B, a fully automated solid-phase synthesis workflow that converts multistep, resin-bound chemistry into crude screening libraries that can be assayed directly, expanding reaction scope well beyond the reach of solution-phase D2B. We applied AutoSPS-D2B to explore several distinct chemotypes as allosteric ligands for the immuno-oncology target CCR2. Good agreement was observed in the relative binding affinity trends between crude and pure screening compounds, enabling streamlined ranking of analogues and prioritisation of hits for further investigation. When applied to the advancement of a previously underexplored CCR2 hit, AutoSPS-D2B enabled an analogue space of more than 1,700 building block combinations to be rapidly sampled, leading to optimised compounds with up to six-fold binding affinity improvements in just two DMTA cycles. This work establishes automated SPS as a versatile and efficient engine for D2B-driven hit-to-lead discovery.
- 13 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAutoSPS-D2B: Automated Solid-Phase Synthesis Expands the Reaction Scope for Direct-to-Biology Libraries
Direct-to-biology (D2B) has emerged as a powerful accelerant in early drug discovery, bypassing compound purification to compress the design-make-test-analyse (DMTA) cycle. However, the chemistry underpinning D2B libraries is limited to just a few sequential transformations using assay-compatible reagents and solvents. By contrast, solid-phase synthesis (SPS) empowers a far broader range of reactions and is highly amenable to multistep synthesis, yet its potential as a source for D2B libraries remains largely underexplored. In this study, we develop AutoSPS-D2B, a fully automated solid-phase synthesis workflow that converts multistep, resin-bound chemistry into crude screening libraries that can be assayed directly, expanding reaction scope well beyond the reach of solution-phase D2B. We applied AutoSPS-D2B to explore several distinct chemotypes as allosteric ligands for the immuno-oncology target CCR2. Good agreement was observed in the relative binding affinity trends between crude and pure screening compounds, enabling streamlined ranking of analogues and prioritisation of hits for further investigation. When applied to the advancement of a previously underexplored CCR2 hit, AutoSPS-D2B enabled an analogue space of more than 1,700 building block combinations to be rapidly sampled, leading to optimised compounds with up to six-fold binding affinity improvements in just two DMTA cycles. This work establishes automated SPS as a versatile and efficient engine for D2B-driven hit-to-lead discovery.
- Open Access
Rational Design of a Photoactivated Fluorescent Probe for Thiol-ene Mediated Protein Labelling
Fluorescent labelling of biomolecules enables the visualization and tracking of molecular processes in cells, providing insights into cellular function and disease mechanisms. Despite recent advances in bioorthogonal labelling, efficient and site-selective strategies for targeting alkene functionalities remain limited. Here, we report AbzSH, a compact aminobenzamide-based fluorescent thiol probe for selective alkene labelling through thiol–ene ligation. Photoinduced ligation proceeds under mild, radical-mediated conditions in aqueous media and exhibits broad substrate compatibility, including carbohydrate, amino acid, and steroid scaffolds. The method is readily extended to protein labelling, enabling selective modification of both chemically functionalized proteins and engineered proteins containing genetically encoded alkene motifs. Efficient and chemoselective labelling was further demonstrated in complex cell lysates, highlighting the robustness of the approach in biologically relevant environments. Collectively, these results establish AbzSH as a versatile fluorescent probe for alkene-directed biomolecular labelling and provide a broadly applicable platform for chemical biology, molecular imaging, proteomics, and drug discovery. TOC Graphic: Thiol-ene mediated ‘click’ labelling of an alkene-bearing protein in complex cell lysate using a fluorescent thiol probe.
Open AccessRational Design of a Photoactivated Fluorescent Probe for Thiol-ene Mediated Protein Labelling
Fluorescent labelling of biomolecules enables the visualization and tracking of molecular processes in cells, providing insights into cellular function and disease mechanisms. Despite recent advances in bioorthogonal labelling, efficient and site-selective strategies for targeting alkene functionalities remain limited. Here, we report AbzSH, a compact aminobenzamide-based fluorescent thiol probe for selective alkene labelling through thiol–ene ligation. Photoinduced ligation proceeds under mild, radical-mediated conditions in aqueous media and exhibits broad substrate compatibility, including carbohydrate, amino acid, and steroid scaffolds. The method is readily extended to protein labelling, enabling selective modification of both chemically functionalized proteins and engineered proteins containing genetically encoded alkene motifs. Efficient and chemoselective labelling was further demonstrated in complex cell lysates, highlighting the robustness of the approach in biologically relevant environments. Collectively, these results establish AbzSH as a versatile fluorescent probe for alkene-directed biomolecular labelling and provide a broadly applicable platform for chemical biology, molecular imaging, proteomics, and drug discovery. TOC Graphic: Thiol-ene mediated ‘click’ labelling of an alkene-bearing protein in complex cell lysate using a fluorescent thiol probe.
- Open Access
PROXINAUT: An Automation Platform for Rapid Hit-to-Degrader Discovery
Massive library-based platforms enable rapid early hit discovery, yet subsequent hit resynthesis and validation remain major bottlenecks in drug discovery. This delay is amplified when optimizing hits, or elaborating structures towards more advanced modalities, such as chemical inducers of proximity (CIPs). Here, we report PROXINAUT, an end-to-end workflow integrating self-encoded library-based hit discovery with an automated parallel solid-phase synthesis platform to streamline hit discovery, validation, optimization, and degrader development. As a demonstration, screening a 176k-member benzimidazole library against BRD4 yielded six hit candidates, which were obtained via parallel automated synthesis and validated as submicromolar binders. The automation workflow empowered a rapid structure activity relationship exploration around the whole scaffold and resulted in a variant with six-fold improved binding affinity. Next, we aimed to automatize the development of bifunctional degraders. Solid phase synthesis typically leaves a C-terminal amide as a synthetic artifact that can compromise druglike properties. We developed a strategy to repurpose this resin-attachment site, converting it into functional degrons featuring either FBXO31-targeting C-terminal amides or cereblon-binding cyclic imides. Operating without human intervention, our automated platform executes up to 16 synthetic steps across multiple parallel structures, enabling true de novo synthesis of full bifunctional scaffolds, where ligand, linker and E3 recruiter variations can all be explored within the same workflow. This resulted in cell-active BRD4 degraders with subnanomolar to nanomolar potency. Overall, we show how library selections can merge with multi-step parallel automation to convert hits directly into validated leads and advanced degrader modalities.
Open AccessPROXINAUT: An Automation Platform for Rapid Hit-to-Degrader Discovery
Massive library-based platforms enable rapid early hit discovery, yet subsequent hit resynthesis and validation remain major bottlenecks in drug discovery. This delay is amplified when optimizing hits, or elaborating structures towards more advanced modalities, such as chemical inducers of proximity (CIPs). Here, we report PROXINAUT, an end-to-end workflow integrating self-encoded library-based hit discovery with an automated parallel solid-phase synthesis platform to streamline hit discovery, validation, optimization, and degrader development. As a demonstration, screening a 176k-member benzimidazole library against BRD4 yielded six hit candidates, which were obtained via parallel automated synthesis and validated as submicromolar binders. The automation workflow empowered a rapid structure activity relationship exploration around the whole scaffold and resulted in a variant with six-fold improved binding affinity. Next, we aimed to automatize the development of bifunctional degraders. Solid phase synthesis typically leaves a C-terminal amide as a synthetic artifact that can compromise druglike properties. We developed a strategy to repurpose this resin-attachment site, converting it into functional degrons featuring either FBXO31-targeting C-terminal amides or cereblon-binding cyclic imides. Operating without human intervention, our automated platform executes up to 16 synthetic steps across multiple parallel structures, enabling true de novo synthesis of full bifunctional scaffolds, where ligand, linker and E3 recruiter variations can all be explored within the same workflow. This resulted in cell-active BRD4 degraders with subnanomolar to nanomolar potency. Overall, we show how library selections can merge with multi-step parallel automation to convert hits directly into validated leads and advanced degrader modalities.
- Open Access
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
Exploring the Intracellular Allosteric Binding Site of CC Chemokine Receptor 5 with a Novel Radioligand and Mutagenesis
CC chemokine receptor 5 (CCR5), a well-established HIV-1 coreceptor and key mediator of inflammatory and autoimmune diseases, has long been targeted exclusively through its extracellular orthosteric binding site. Recently, several homologous CC chemokine receptors, i.e. CCR2, CCR4, CCR7, and CCR9, have been crystalized in complex with antagonists targeting an intracellular allosteric binding site (IABS). For CCR5, however, definitive evidence for such an intracellular site has remained elusive, despite multiple reports of putative intracellular allosteric antagonists.To address this, we radiolabelled a putative intracellular allosteric antagonist, [3H]LUF7721, which displayed nanomolar affinity for CCR5. Several putative allosteric antagonists fully displaced [3H]LUF7721, whereas the orthosteric antagonist BMS-813160 enhanced [3H]LUF7721 binding, consistent with distinct binding sites and allosteric cooperativity.Guided by computational methods and literature data, our mutagenesis study identified key interaction residues within the CCR5 IABS. Five mutations markedly reduced [3H]LUF7721 binding, while substitution of L2366.36 with the CCR2 reciprocal residue (valine) doubled LUF7721 affinity, while attenuating BMS-813160 cooperative potency. Computational modelling was used for binding pose proposition and to generate mechanistic insights with molecular dynamics simulations. The simulations revealed a structural basis by which L2366.36 may drive the selectivity of intracellular ligands for CCR5 versus CCR2, offering insights into selective targeting of this IABS.Collectively, this study reports the first intracellular allosteric radioligand for CCR5 and characterizes its intracellular binding site through mutagenesis and computational modelling. These findings establish a foundation for the development of novel CCR5 inhibitors targeting this site with therapeutic potential.
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessExploring the Intracellular Allosteric Binding Site of CC Chemokine Receptor 5 with a Novel Radioligand and Mutagenesis
CC chemokine receptor 5 (CCR5), a well-established HIV-1 coreceptor and key mediator of inflammatory and autoimmune diseases, has long been targeted exclusively through its extracellular orthosteric binding site. Recently, several homologous CC chemokine receptors, i.e. CCR2, CCR4, CCR7, and CCR9, have been crystalized in complex with antagonists targeting an intracellular allosteric binding site (IABS). For CCR5, however, definitive evidence for such an intracellular site has remained elusive, despite multiple reports of putative intracellular allosteric antagonists.To address this, we radiolabelled a putative intracellular allosteric antagonist, [3H]LUF7721, which displayed nanomolar affinity for CCR5. Several putative allosteric antagonists fully displaced [3H]LUF7721, whereas the orthosteric antagonist BMS-813160 enhanced [3H]LUF7721 binding, consistent with distinct binding sites and allosteric cooperativity.Guided by computational methods and literature data, our mutagenesis study identified key interaction residues within the CCR5 IABS. Five mutations markedly reduced [3H]LUF7721 binding, while substitution of L2366.36 with the CCR2 reciprocal residue (valine) doubled LUF7721 affinity, while attenuating BMS-813160 cooperative potency. Computational modelling was used for binding pose proposition and to generate mechanistic insights with molecular dynamics simulations. The simulations revealed a structural basis by which L2366.36 may drive the selectivity of intracellular ligands for CCR5 versus CCR2, offering insights into selective targeting of this IABS.Collectively, this study reports the first intracellular allosteric radioligand for CCR5 and characterizes its intracellular binding site through mutagenesis and computational modelling. These findings establish a foundation for the development of novel CCR5 inhibitors targeting this site with therapeutic potential.
- Open Access
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Massive barcode-free chemical screenings enable the discovery of bioactive macrocycles with passive membrane permeability
Synthetic macrocycles offer exceptional potential as therapeutics. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically are not optimized for drug like properties. Fully synthetic libraries offer greater flexibility in accessing broader chemical space. Leveraging recent advances in mass spectrometry based library techniques, here we report CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow, that screens synthetic macrocycle libraries enriched in drug-like ‘beyond rule of five’ features. The workflow relies on affinity selections and hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes. We construct a 16 million-member library and validate the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WD repeat-containing protein 5 (WDR5) yields a macrocycle with subnamolar affinity, and potent inhibition of the WDR5–Mixed-Lineage Leukemia 1 (MLL1) interaction. Subsequent modifications produce a chameleonic macrocycle with passive membrane permeability, serum stability, and anti-proliferative activity in leukemia cells. Together, these results demonstrate that CycloSEL enables discovery of drug-like macrocycles from fully synthetic libraries for intracellular targets.
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMassive barcode-free chemical screenings enable the discovery of bioactive macrocycles with passive membrane permeability
Synthetic macrocycles offer exceptional potential as therapeutics. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically are not optimized for drug like properties. Fully synthetic libraries offer greater flexibility in accessing broader chemical space. Leveraging recent advances in mass spectrometry based library techniques, here we report CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow, that screens synthetic macrocycle libraries enriched in drug-like ‘beyond rule of five’ features. The workflow relies on affinity selections and hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes. We construct a 16 million-member library and validate the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WD repeat-containing protein 5 (WDR5) yields a macrocycle with subnamolar affinity, and potent inhibition of the WDR5–Mixed-Lineage Leukemia 1 (MLL1) interaction. Subsequent modifications produce a chameleonic macrocycle with passive membrane permeability, serum stability, and anti-proliferative activity in leukemia cells. Together, these results demonstrate that CycloSEL enables discovery of drug-like macrocycles from fully synthetic libraries for intracellular targets.
- Open Access
- 18 February 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Automated Parallel Synthesis Accelerates Virtual Screening Hit Discovery
Virtual screening (VS) is a powerful approach to explore vast chemical space, encompassing libraries of millions to billions of compounds. However, the low hit rates of VS require testing numerous candidates to validate true binders, followed by iterative optimization cycles, making experimental validation costly and time-consuming. Here, we report COMBINAUT, an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement. Using a faculty-wide collection of in-house building blocks, the system enables enumeration of over 22.9 million compounds, each designed for parallelized synthesis within 1-32 hours using repurposed solid-phase peptide synthesis equipment. Using this platform, we performed large-scale virtual screening targeting the allosteric pocket of the immuno-oncology target, C-C chemokine receptor 2 (CCR2). Our approach facilitated the rapid synthesis and testing of 100 virtual screening hits, spanning diverse molecular architectures. In radioligand binding assays, we successfully validated nine hits with distinct scaffolds, including completely novel CCR2 ligand chemotypes. Iterative hit-to-lead optimization using the automated workflow produced cell-active CCR2 antagonists. This work demonstrates the synergy of automated synthesis and VS, enabling efficient exploration of chemical space and rapid discovery of novel ligands.
- 18 February 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAutomated Parallel Synthesis Accelerates Virtual Screening Hit Discovery
Virtual screening (VS) is a powerful approach to explore vast chemical space, encompassing libraries of millions to billions of compounds. However, the low hit rates of VS require testing numerous candidates to validate true binders, followed by iterative optimization cycles, making experimental validation costly and time-consuming. Here, we report COMBINAUT, an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement. Using a faculty-wide collection of in-house building blocks, the system enables enumeration of over 22.9 million compounds, each designed for parallelized synthesis within 1-32 hours using repurposed solid-phase peptide synthesis equipment. Using this platform, we performed large-scale virtual screening targeting the allosteric pocket of the immuno-oncology target, C-C chemokine receptor 2 (CCR2). Our approach facilitated the rapid synthesis and testing of 100 virtual screening hits, spanning diverse molecular architectures. In radioligand binding assays, we successfully validated nine hits with distinct scaffolds, including completely novel CCR2 ligand chemotypes. Iterative hit-to-lead optimization using the automated workflow produced cell-active CCR2 antagonists. This work demonstrates the synergy of automated synthesis and VS, enabling efficient exploration of chemical space and rapid discovery of novel ligands.
- Open Access
- 27 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Barcode-free hit discovery from massive libraries enabled by automated small molecule structure annotation
Affinity-selection platforms are powerful tools in early drug discovery, but current technologies – most notably DNA-encoded libraries (DELs) – are limited by synthesis complexity and incompatibility with nucleic acid-binding targets. We present a barcode-free self-encoded library (SEL) platform that enables direct screening of over half a million small molecules in a single experiment. SELs combine tandem mass spectrometry with custom software for automated structure annotation, eliminating the need for external tags for the identification of screening hits. We develop efficient, high-diversity synthesis protocols for a broad range of chemical scaffolds and benchmark the platform in affinity selections against carbonic anhydrase IX, identifying multiple nanomolar binders. We further apply SELs to flap endonuclease 1 (FEN1) – a disease related DNA-processing enzyme inaccessible to DELs – and discover potent inhibitors. Taken together, screening barcode-free libraries of this scale all at once represents an important development, enables access to novel target classes, and promises substantial impact on both academic and industrial early drug discovery.
- 27 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Open AccessBarcode-free hit discovery from massive libraries enabled by automated small molecule structure annotation
Affinity-selection platforms are powerful tools in early drug discovery, but current technologies – most notably DNA-encoded libraries (DELs) – are limited by synthesis complexity and incompatibility with nucleic acid-binding targets. We present a barcode-free self-encoded library (SEL) platform that enables direct screening of over half a million small molecules in a single experiment. SELs combine tandem mass spectrometry with custom software for automated structure annotation, eliminating the need for external tags for the identification of screening hits. We develop efficient, high-diversity synthesis protocols for a broad range of chemical scaffolds and benchmark the platform in affinity selections against carbonic anhydrase IX, identifying multiple nanomolar binders. We further apply SELs to flap endonuclease 1 (FEN1) – a disease related DNA-processing enzyme inaccessible to DELs – and discover potent inhibitors. Taken together, screening barcode-free libraries of this scale all at once represents an important development, enables access to novel target classes, and promises substantial impact on both academic and industrial early drug discovery.
- Open Access
- 5 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
CycloSELs – Massive Screening Platform of barcode-free macrocycle libraries enables the identification of cell-penetrating PPI inhibitors
Synthetic macrocycles offer exceptional potential as therapeutics, combining the ability to engage challenging biological targets with favorable drug-like properties. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically exhibit poor cell permeability. Here we report CycloSEL (Cyclic Self-Encoded Libraries): a barcode-free, fully synthetic, ultra–high-throughput platform for the discovery of drug-like macrocycles. CycloSEL couples the combinatorial synthesis of massive macrocycle libraries with affinity-based selection and de novo hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes and expanding chemical space. We constructed a 16 million-member macrocycle library enriched in druglike features and validated the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WDR5 yielded a macrocycle with 8 nM affinity, which we rapidly optimized to a compound that potently disrupts the oncogenic WDR5–MLL interaction (IC₅₀ = 128 nM), displays excellent serum stability, passive membrane permeability and anti-proliferative activity against leukemia cells. Taken together, CycloSEL is a powerful discovery platform for identifying therapeutic leads against challenging intracellular targets.
- 5 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCycloSELs – Massive Screening Platform of barcode-free macrocycle libraries enables the identification of cell-penetrating PPI inhibitors
Synthetic macrocycles offer exceptional potential as therapeutics, combining the ability to engage challenging biological targets with favorable drug-like properties. However, most high-throughput discovery platforms rely on genetically encoded libraries of large peptide macrocycles, which typically exhibit poor cell permeability. Here we report CycloSEL (Cyclic Self-Encoded Libraries): a barcode-free, fully synthetic, ultra–high-throughput platform for the discovery of drug-like macrocycles. CycloSEL couples the combinatorial synthesis of massive macrocycle libraries with affinity-based selection and de novo hit identification by tandem mass spectrometry, eliminating the need for genetic barcodes and expanding chemical space. We constructed a 16 million-member macrocycle library enriched in druglike features and validated the approach against the oncology target carbonic anhydrase IX, achieving robust enrichment and accurate identification of true binders. Applying CycloSEL to the acute myeloid leukemia target WDR5 yielded a macrocycle with 8 nM affinity, which we rapidly optimized to a compound that potently disrupts the oncogenic WDR5–MLL interaction (IC₅₀ = 128 nM), displays excellent serum stability, passive membrane permeability and anti-proliferative activity against leukemia cells. Taken together, CycloSEL is a powerful discovery platform for identifying therapeutic leads against challenging intracellular targets.
- Open Access
- 26 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Barcode-free hit discovery from massive libraries enabled by automated small molecule structure annotation
Affinity-selection platforms are powerful tools in early drug discovery, but current technologies – most notably DNA-encoded libraries (DELs) – are limited by synthesis complexity and incompatibility with nucleic acid-binding targets. We present a barcode-free self-encoded library (SEL) platform that enables direct screening of ~1 million small molecules in a single experiment. SELs combine tandem mass spectrometry with custom software for automated structure annotation, eliminating the need for external tags for the identification of screening hits. We developed efficient, high-diversity synthesis protocols for a broad range of chemical scaffolds and benchmarked the platform in affinity selections against carbonic anhydrase IX, identifying multiple nanomolar binders. We further applied SELs to flap endonuclease 1 (FEN1) – a disease related DNA-processing enzyme inaccessible to DELs – and discovered potent inhibitors. Taken together, screening barcode-free libraries of this scale is unprecedented, enables access to novel target classes, and promises substantial impact on both academic and industrial early drug discovery.
- 26 May 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBarcode-free hit discovery from massive libraries enabled by automated small molecule structure annotation
Affinity-selection platforms are powerful tools in early drug discovery, but current technologies – most notably DNA-encoded libraries (DELs) – are limited by synthesis complexity and incompatibility with nucleic acid-binding targets. We present a barcode-free self-encoded library (SEL) platform that enables direct screening of ~1 million small molecules in a single experiment. SELs combine tandem mass spectrometry with custom software for automated structure annotation, eliminating the need for external tags for the identification of screening hits. We developed efficient, high-diversity synthesis protocols for a broad range of chemical scaffolds and benchmarked the platform in affinity selections against carbonic anhydrase IX, identifying multiple nanomolar binders. We further applied SELs to flap endonuclease 1 (FEN1) – a disease related DNA-processing enzyme inaccessible to DELs – and discovered potent inhibitors. Taken together, screening barcode-free libraries of this scale is unprecedented, enables access to novel target classes, and promises substantial impact on both academic and industrial early drug discovery.